Francisco Trust Under Agreemen Sells 15,000 Shares of Dyadic International (NASDAQ:DYAI) Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $2.01, for a total value of $30,150.00. Following the transaction, the insider owned 3,375,664 shares of the company’s stock, valued at approximately $6,785,084.64. This represents a 0.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Dyadic International Price Performance

Shares of Dyadic International stock opened at $0.94 on Monday. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.42 and a quick ratio of 2.42. Dyadic International Inc. has a 1-year low of $0.65 and a 1-year high of $1.35. The business’s fifty day moving average price is $0.77 and its two-hundred day moving average price is $0.83. The company has a market capitalization of $34.27 million, a P/E ratio of -4.09 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The business had revenue of $1.11 million during the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. As a group, research analysts forecast that Dyadic International Inc. will post 0.13 EPS for the current year.

Hedge Funds Weigh In On Dyadic International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares in the last quarter. Marathon Capital Management bought a new stake in shares of Dyadic International in the 3rd quarter worth $41,000. Geode Capital Management LLC lifted its holdings in shares of Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the period. Landscape Capital Management L.L.C. acquired a new stake in shares of Dyadic International in the third quarter valued at $190,000. Finally, Apis Capital Advisors LLC acquired a new stake in shares of Dyadic International in the third quarter valued at $1,817,000. 27.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.